GSK announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The investment includes a new $1.2 billion commitment to advanced manufacturing facilities and AI and advanced
In the rapidly evolving biopharmaceutical landscape, biologics or ‘large molecule’ therapies have emerged as a crucial segment, promising innovative treatments for a wide-range of diseases. 90% of biotechs choose to partner with a Contract Development and Manufacturing Organisation (CDMO) to
Skyepharma is a fully-integrated CDMO specialised in formulating, developing and producing complex oral dosage forms and expanding into Bioproduction with the opening of their new SkyeHub plant. Based outside Lyon, France, the company offers their worldwide customer base a full
“If you can’t demonstrate international quality standards, nobody is going to take a chance on a million-dollar batch to save a few dollars on their manufacturing. It just won’t happen.” Eric Langer is President of BioPlan Associates, where he has
“Biotechs need flexibility and have limited budgets, while big pharma looks for long-term partnerships, reliability, scalability, and new technologies.” Luis Berrade, Senior Director of Global Biologics Testing Sales at Charles River Laboratories, has spent his career helping pharmaceutical and biotech
